Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple diet switch calm IBS? a trial puts two popular eating plans to the test.

NCT ID NCT07722572

Symptom relief Sponsor: Antalya Bilim University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial compares two diets—low-FODMAP and lactose- and gluten-free—in adults with irritable bowel syndrome (IBS). Each participant tries both diets for four weeks, with a one-week break in between, to see which one better reduces gut symptoms and improves mental health. The goal is to find out whether one diet offers clearer benefits for people struggling with IBS.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a low-FODMAP diet and a lactose- and gluten-free diet
What this could lead to
If one diet clearly outperforms the other, this could help doctors recommend a simpler or more effective first-line dietary approach for IBS.
What could go wrong
This is a relatively small crossover trial with only 72 participants, so results may not apply to everyone with IBS. Dietary adherence can be challenging, and the one-week washout may not fully reset gut symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

72 people

The number who actually took part.

Started

Sep 2020

Finished

Jan 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 64 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18-64 years. * Diagnosis of Irritable Bowel Syndrome according to the Rome III criteria. * Ability and willingness to comply with the dietary intervention. * Written informed consent provided. Exclusion Criteria: * Pregnancy or lactation. * Diabetes mellitus. * Organic gastrointestinal disease. * Current follow-up for cardiologic, neurologic, oncologic, or psychiatric disorders. * Following a therapeutic diet within 1 month before enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Irritable bowel syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety disorder irritable bowel syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Irritable bowel syndrome

Contacts and locations

Locations

  • Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Gastroenterology

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.